Tetra Bio-Pharma Initiates Additional Studies on Leading Drug Candidate ARDS-003

Rhea-AI Summary

Tetra Bio-Pharma has entered an agreement with Targeted Pharmaceuticals to collaborate on the Antiviral Central Nervous System Program. This partnership aims to advance the research of ARDS-003, focusing on its potential in treating neuroinflammation and other antiviral applications. The global market for central nervous system drugs is projected to grow from $125.28 billion in 2020 to $163.05 billion by 2025, highlighting significant opportunities in this field. CEO Dr. Guy Chamberland emphasizes the importance of this collaboration for expanding investment returns on ARDS-003.

Positive

• Strategic partnership with Targeted Pharmaceuticals to advance ARDS-003 research.
• Access to the growing central nervous system drugs market, projected to reach $163.05 billion by 2025.

Negative

• None.

• Tetra Bio-Pharma and Targeted Pharmaceuticals enter into an agreement to further its collaboration and co-development activities to advance Antiviral Central Nervous System Program
• The addressable global market for central nervous system drugs is expected to grow to $163.05 billion in 2025

OTTAWA, ON / ACCESSWIRE / March 26, 2021 / Tetra Bio-Pharma Inc. ("Tetra" or the "Company") (TSX:TBP)(OTCQB:TBPMF)(FRA:JAM1), a biopharmaceutical pioneer in immunomodulator drug discovery and development announce they have initiated other research projects with Targeted Pharmaceuticals through its research agreement with the George Mason University NCBID to investigate the potential benefits of ARDS-003 in neuroinflammation and other antiviral applications.

The global central nervous system drugs market is expected to grow from $125.28 billion in 2020 to $163.05 billion in 2025 at a CAGR of 6%. (ref: Feb 2021, The Business research company).

Dr. Guy Chamberland, CEO and CRO commented, "We have initiated this new research agreement to further understand the potential therapeutic benefits of ARDS-003 in treating inflammatory conditions of the brain as well as learning more about the potential use of the drug candidate in other antiviral applications. The partnership with Targeted provides expertise into these areas of drug development that are critical for expanding the potential Return on Investment of our lead drug candidate ARDS-003."

About Tetra Bio-Pharma

Tetra Bio-Pharma (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) is a biopharmaceutical pioneer in immunomodulator drug discovery and development with a FDA and a Health Canada cleared clinical program aimed at bringing novel prescription drugs and treatments to patients and their healthcare providers. Our evidence-based scientific approach has enabled us to develop a pipeline of cannabinoid-based drug products for a range of medical conditions, including pain, inflammation, and oncology. With patients at the core of what we do, Tetra Bio-Pharma is focused on providing rigorous scientific validation and safety data required for inclusion into the existing biopharma industry by regulators, physicians and insurance companies.

For more information visit: www.tetrabiopharma.com

About Targeted Pharmaceuticals LLC

Targeted Pharmaceuticals is a clinical-stage pharmaceutical company focused on treatments for oncology and central nervous system disorders.

Learn more at https://www.targetedpharma.com

About George Mason University

George Mason University is Virginia's largest public research university. Located near Washington, D.C., Mason enrolls more than 37,000 students from 130 countries and all 50 states. The National Center for Biodefense and Infectious Diseases (NCBID) at Mason focuses on host-pathogen interactions using proteomics and nanotechnology as they are applied to diagnostic, therapeutic, and vaccine development. NCBID manages The Biomedical Research Lab (BRL), one of thirteen Regional Biocontainment Laboratories in the U.S. constructed with funding support from the National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIAID/NIH), performing pioneering research of infectious diseases, both emerging and potential bio threat agents.

Learn more at www.ncbid.gmu.edu

The College of Science at Mason is a leader in scientific discovery creating innovative solutions for the rapidly changing needs of today's world. Mason's College of Science blends traditional science education with sought-after programs in disciplines as diverse as personalized medicine, infectious diseases, geoinformatics, climate dynamics, materials science, astronomy, forensic science, and applied mathematics. The College encourages meaningful education and research at all levels offering innovative undergraduate programs, minors, certificates, and graduate degree opportunities, as well as global, transfer-focused, and online, or hybrid, programs that allow professionals the opportunity to reskill or change careers.

Learn more at www.science.gmu.edu

Neither the TSX Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words "may", "will", "should", "continue", "expect", "anticipate", "estimate", "believe", "intend", "plan" or "project" or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company's ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company to obtain sufficient financing to execute the Company's business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company's research and development strategies, including the success of this product or any other product, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company's public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

For further information, please contact Tetra Bio-Pharma Inc.:

Tetra Bio-Pharma Inc.
Ms. Natalie Leroux
Phone: + 1 (833) 977-7575
Email: investors@tetrabiopharma.com
media@tetrabiopharma.com

SOURCE: Tetra Bio-Pharma

View source version on accesswire.com:
https://www.accesswire.com/637560/Tetra-Bio-Pharma-Initiates-Additional-Studies-on-Leading-Drug-Candidate-ARDS-003

FAQ

What is Tetra Bio-Pharma's recent agreement about?

Tetra Bio-Pharma has partnered with Targeted Pharmaceuticals to co-develop its ARDS-003 drug candidate for neuroinflammation and antiviral applications.

How much is the central nervous system drugs market expected to grow?

The global central nervous system drugs market is projected to grow from $125.28 billion in 2020 to $163.05 billion by 2025.

What is the stock symbol for Tetra Bio-Pharma?

The stock symbol for Tetra Bio-Pharma is TBPMF on the OTCQB.

What are the research objectives for ARDS-003?

The objectives include understanding its therapeutic benefits in treating brain inflammatory conditions and exploring its use for other antiviral applications.